Literature DB >> 7002673

Quantitative estimation of beta cell sensitivity to glucose in the intact organism: a minimal model of insulin kinetics in the dog.

G Toffolo, R N Bergman, D T Finegood, C R Bowden, C Cobelli.   

Abstract

We propose an approach to quantifying the sensitivity of B cells to glucose in the intact organism, whereby we interpret the complex dynamic plasma insulin response to glucose injection in terms of a minimal mathematical model of posthepatic insulin delivery and insulin clearance. The best model for this purpose was chosen by comparing the ability of a series of proposed models to account precisely for plasma insulin dynamics. Intravenous glucose tolerance tests (IVGTT) (300 mg/kg) were performed on conscious dogs, and blood was sampled frequently until the basal steady state was reestablished. Glucose injection produced variable plasma insulin responses, which were characterized by an early peak (76 microU/ml above basal), a plateau with occasional additional peaks, and by an abrupt return of plasma insulin to basal by 37 min. A set of eight models was examined; one emerged as superior, in that it was able to account for insulin dynamics with the smallest number of physiologically meaningful parameters (N = 4). The chosen (minimal) model assumes that (1) clearance of insulin is of the first order, (2) the initial peak represents a bolus of insulin loaded into the plasma after the glucose injection, and (3) the rate of the secondary rise in insulin is determined by the concentration of glucose in plasma above a specific threshold value. The sensitivity of first phase insulin delivery to glucose (phi 1; 1.28 +/- 0.15 microU/ml per min per mg/dl), the sensitivity of the secondary phase to glucose concentration [phi 2; 0.038 +/- 0.005 (microU/mg) . min-2], and the threshold for glucose stimulation of second phase secretion (h; 125 +/- 8 mg/100 ml) were all precisely estimated from the dynamic insulin responses. These three parameters of insulin kinetics (phi 1, phi 2, and h) can be calculated from a single IVGTT, and they characterize the insulin responsiveness of a single individual. Estimating these characteristic parameters of insulin kinetics from IVGTT data has potential for quantitating the individual factors contributing to glucose-stimulated insulin secretion in intact animal models, and it may be applicable to man.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7002673     DOI: 10.2337/diab.29.12.979

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  41 in total

1.  Effects of high-dose troglitaz one on insulin sensitivity and beta-cell function in Watanabe heritable hyperlipidemic rabbits.

Authors:  B Zhang; M Shiomi; H Tanaka; J Mei; P Fan; Y Tsujita; H Horikoshi; K Saku
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Jul-Sep       Impact factor: 2.441

2.  A switching control strategy for the attenuation of blood glucose disturbances.

Authors:  Mihalis G Markakis; Georgios D Mitsis; George P Papavassilopoulos; Petros A Ioannou; Vasilis Z Marmarelis
Journal:  Optim Control Appl Methods       Date:  2011       Impact factor: 2.530

3.  Glycemia prediction in critically ill patients using an adaptive modeling approach.

Authors:  Tom Van Herpe; Marcelo Espinoza; Niels Haverbeke; Bart De Moor; Greet Van den Berghe
Journal:  J Diabetes Sci Technol       Date:  2007-05

4.  Bifurcation analysis in a delay model of IVGTT glucose-insulin interaction.

Authors:  Fateme Mohabati; MohammadReza Molaei
Journal:  Theory Biosci       Date:  2019-07-22       Impact factor: 1.919

Review 5.  Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus.

Authors:  Cornelia B Landersdorfer; William J Jusko
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

6.  In vivo kinetics of insulin action on peripheral glucose disposal and hepatic glucose output in normal and obese subjects.

Authors:  R Prager; P Wallace; J M Olefsky
Journal:  J Clin Invest       Date:  1986-08       Impact factor: 14.808

7.  Advantages of the single delay model for the assessment of insulin sensitivity from the intravenous glucose tolerance test.

Authors:  Simona Panunzi; Andrea De Gaetano; Geltrude Mingrone
Journal:  Theor Biol Med Model       Date:  2010-03-18       Impact factor: 2.432

8.  Preclinical PK/PD modeling and human efficacious dose projection for a glucokinase activator in the treatment of diabetes.

Authors:  Michael G Zager; Kirk Kozminski; Bernadette Pascual; Kathleen M Ogilvie; Shaoxian Sun
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-02-28       Impact factor: 2.745

Review 9.  Beta cell function and its relation to insulin action in humans: a critical appraisal.

Authors:  E Ferrannini; A Mari
Journal:  Diabetologia       Date:  2004-04-23       Impact factor: 10.122

10.  Application of the integrated glucose-insulin model for cross-study characterization of T2DM patients on metformin background treatment.

Authors:  Joanna Parkinson; Bengt Hamrén; Maria C Kjellsson; Stanko Skrtic
Journal:  Br J Clin Pharmacol       Date:  2016-08-16       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.